Parabilis Medicines to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference
Parabilis Medicines (Nasdaq: PBLS) announced that its Chairman, President and CEO, Mathai Mammen, M.D., Ph.D., will participate in a fireside chat at the Morgan Stanley 24th Annual Global Healthcare Conference in New York, NY.
Rhea-AI Summary
Parabilis Medicines (Nasdaq: PBLS) announced that its Chairman, President and CEO, Mathai Mammen, M.D., Ph.D., will participate in a fireside chat at the Morgan Stanley 24th Annual Global Healthcare Conference in New York, NY. The session is scheduled for 2:35 PM ET on Wednesday, September 16, 2026, with a live audio webcast available via the Investors section of the Parabilis website.
Positive
- None.
Negative
- None.
News Market Reaction – PBLS
In the Sep 1 session, PBLS gained 1.47%, reflecting a mild positive market reaction. Trading volume was exceptionally heavy at 8.9x the daily average, suggesting very strong buying interest.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Aug 25 | board appointment | Positive | +2.2% | New director with more than 30 years of oncology development experience |
| Aug 13 | quarterly earnings | Negative | -5.0% | Earnings report included a $52.5M net loss and increased operating investment |
| Jun 11 | IPO closing | Positive | -10.1% | Upsized IPO closed with 38,525,000 shares priced at $20.00 per share |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent reactions varied, ranging from a 2.16% gain after management news to declines after earnings and IPO announcements.
AI-generated analysis. How Rhea-AI works. Not financial advice.
CAMBRIDGE, Mass., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Parabilis Medicines (Nasdaq: PBLS), a clinical-stage biopharmaceutical company dedicated to creating extraordinary medicines for patients with serious diseases by unlocking historically undruggable targets, today announced its Chairman, President and Chief Executive Officer Mathai Mammen, M.D., Ph.D., will participate in a fireside chat at the Morgan Stanley 24th Annual Global Healthcare Conference in New York, NY at 2:35 PM ET on Wednesday, September 16, 2026.
The live audio webcast will be available on the Investors section of the Parabilis website at investors.parabilismed.com.
About Parabilis Medicines
Parabilis Medicines (Nasdaq: PBLS) is a clinical-stage biopharmaceutical company dedicated to creating extraordinary medicines for patients with serious diseases by unlocking biologically important targets long considered undruggable. The company has pioneered a new class of alpha-helical peptides – Helicons™ – capable of modulating intracellular proteins that have historically been beyond the reach of conventional medicines. The company’s lead investigational medicine, zolucatetide, is the first and only direct inhibitor of the β-catenin:TCF interaction, a central node in the Wnt/β-catenin pathway that has eluded drug developers for decades. Zolucatetide is being evaluated in the clinic across multiple Wnt/β-catenin-driven diseases, including desmoid tumors, familial adenomatous polyposis (FAP), adamantinomatous craniopharyngioma (ACP), hepatocellular carcinoma (HCC) and a range of other rare and common solid tumor indications. Beyond zolucatetide, Parabilis is pursuing a follow-on β-catenin degrader program and advancing additional Helicon-based programs focused on other challenging targets, including ERG and allosteric ARON in prostate cancer, where we believe our medicines could have life-altering impact. For more information, visit www.parabilismed.com or follow us on LinkedIn.
Media Contact:
Jessica Freifeld
media@parabilismed.com
Investor Contact:
Tom Kotarakos
investors@parabilismed.com
